Get the Stockscreener App
63.81
4.75%
-3.18
After Hours:
63.81
Biomarin Pharmaceutical Inc stock is traded at $63.81, with a volume of 1.72M.
It is down -4.75% in the last 24 hours and down -3.33% over the past month.
See More
Previous Close:
$66.99
Open:
$67.35
24h Volume:
1.72M
Relative Volume:
1.26
Market Cap:
$12.70B
Revenue:
$2.75B
Net Income/Loss:
$322.29M
P/E Ratio:
38.21
EPS:
1.67
Net Cash Flow:
$300.88M
1W Performance:
-6.02%
1M Performance:
-3.33%
6M Performance:
-24.95%
1Y Performance:
-31.63%
1-Day Range:
$63.58
$67.38
1-Week Range:
$63.58
$69.70
52-Week Range:
$61.15
$94.85
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Name
Biomarin Pharmaceutical Inc
Sector
Industry
Phone
(415) 506-6700
Address
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
63.81 | 12.70B | 2.75B | 322.29M | 300.88M | 1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
411.66 | 106.01B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
690.87 | 75.92B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.60 | 39.80B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.51 | 31.02B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
112.43 | 26.95B | 3.30B | -501.07M | 1.03B | -2.1146 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-30-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-20-24 | Upgrade | Bernstein | Mkt Perform → Outperform |
| May-17-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-24 | Initiated | Evercore ISI | Outperform |
| Nov-15-23 | Initiated | Wells Fargo | Overweight |
| Oct-23-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Sep-28-23 | Initiated | Raymond James | Mkt Perform |
| Sep-18-23 | Initiated | UBS | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| Jul-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Feb-22-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-21-23 | Initiated | Citigroup | Neutral |
| Jan-30-23 | Initiated | BMO Capital Markets | Market Perform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Oct-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| Apr-25-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-09-21 | Upgrade | Stifel | Hold → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-04-21 | Resumed | Guggenheim | Buy |
| Mar-01-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Aug-20-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-19-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-19-20 | Downgrade | Stifel | Buy → Hold |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-06-20 | Reiterated | Citigroup | Buy |
| Jan-28-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-27-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-24-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-27-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-23-19 | Resumed | Citigroup | Buy |
| Apr-09-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-18 | Reiterated | Stifel | Buy |
| Aug-03-18 | Reiterated | Stifel | Buy |
View All
Biomarin Pharmaceutical Inc Stock (BMRN) Latest News
Goldman Sachs maintains Buy on BioMarin shares - Investing.com
BioMarin sues Ascendis Pharma over patent infringement By Investing.com - Investing.com Canada
BioMarin sues Ascendis Pharma over patent infringement - Investing.com
BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court - Kilgore News Herald
Wall Street Analysts Predict a 45.86% Upside in BioMarin (BMRN): Here's What You Should Know - Yahoo Finance
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock - Yahoo Finance
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock - MSN
Zacks Research Brokers Raise Earnings Estimates for BMRN - MarketBeat
Alger Launches Russell Innovation ETF To Capitalize On Emerging Innovators - Benzinga
BioMarin Pharmaceutical (NASDAQ:BMRN) Trading 2.4% HigherStill a Buy? - MarketBeat
XBI, NBIX, GILD, BMRN: Large Outflows Detected at ETF - Nasdaq
Zacks.com featured highlights include Leidos, Amazon.com, Halozyme Therapeutics and BioMarin Pharmaceutical - Yahoo Finance
BMRNBioMarin Pharmaceuticals Inc Latest Stock News & Market Updates - StockTitan
BioMarin CEO to Present at J.P. Morgan Healthcare Conference 2024 - StockTitan
BioMarin plans €60m expansion at Shanbally site - The Southern Star
Layoff Tracker: Regeneron Acquisition of Oxular Wipes Out Oxular Workforce - BioSpace
3 Reasons Why Growth Investors Shouldn't Overlook BioMarin (BMRN) - Yahoo Finance
BMRN or TECH: Which Is the Better Value Stock Right Now? - Yahoo Finance
Global Mucopolysaccharidosis Treatment Market to Witness Robust Growth, Projected to Reach USD 5,014.5 Million by 2035 Growing at a CAGR of 5.9% | FMI - GlobeNewswire Inc.
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term - MSN
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Short Interest Down 9.4% in December - MarketBeat
Sangamo Shares Nosedive as Pfizer Drops Hemophilia Drug Pact - Wall Street Pit
Does BioMarin Pharmaceutical (NASDAQ:BMRN) Have A Healthy Balance Sheet? - Simply Wall St
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term - Yahoo Finance
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Position Trimmed by Principal Financial Group Inc. - MarketBeat
First Week of February 2025 Options Trading For BioMarin Pharmaceutical (BMRN) - Nasdaq
Is the Options Market Predicting a Spike in BioMarin Pharmaceutical (BMRN) Stock? - MSN
Stifel Financial Corp Decreases Stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives $94.20 Average Price Target from Brokerages - MarketBeat
BioMarin's SWOT analysis: rare disease leader's stock faces growth hurdles By Investing.com - Investing.com Canada
BioMarin's SWOT analysis: rare disease leader's stock faces growth hurdles - Investing.com
National Bank of Canada FI Decreases Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Tidal Investments LLC Raises Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Geode Capital Management LLC Acquires 60,692 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Teachers Retirement System of The State of Kentucky Sells 134,167 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Virtu Financial LLC Makes New Investment in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin to Host Investor Day Today at 10:30 a.m. Eastern Time - The Eastern Progress Online
BioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4:30pm ET - The Eastern Progress Online
The Latest Analyst Ratings For Biomarin Pharmaceutical - Benzinga
BioMarin's SWOT analysis: rare disease stock faces growth and competition - Investing.com
Major pharma-company invests €60m in new plant in vote of confidence for Cork - MSN
BioMarin Pharmaceutical (BMRN) is a Top-Ranked Momentum Stock: Should You Buy? - Yahoo Finance
Y Intercept Hong Kong Ltd Buys New Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Acquired by Neo Ivy Capital Management - MarketBeat
Are BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market? - Yahoo Finance
Fmr LLC Buys 36,877 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Pharma giant BioMarin announces €60m investment in Cork facility - MSN
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick - Yahoo Canada Finance
Nomura Asset Management Co. Ltd. Acquires 110,683 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Two Sigma Advisers LP Decreases Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin to add €60M lab to Irish manufacturing site in push to grow production capacity - FiercePharma
Biomarin Pharmaceutical Inc Stock (BMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.13%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):